Biomarin Pharmaceutical (BMRN) Cash from Investing Activities Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn | 196.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.91% |
| Dec 31, 2025 | 8.11% |
| Sep 30, 2025 | -141.83% |
| Jun 30, 2025 | 24.88% |
| Mar 31, 2025 | -32.41% |
| Dec 31, 2024 | 50.05% |
| Sep 30, 2024 | 48.72% |
| Jun 30, 2024 | 40.14% |
| Mar 31, 2024 | 41.41% |
| Dec 31, 2023 | -99.09% |
| Sep 30, 2023 | -34.43% |
| Jun 30, 2023 | 28.44% |
| Mar 31, 2023 | -33.66% |
| Dec 31, 2022 | -3.82% |
| Sep 30, 2022 | -35.37% |
| Jun 30, 2022 | -51.97% |
| Mar 31, 2022 | 55.21% |
| Dec 31, 2021 | 7.91% |
| Sep 30, 2021 | -31.96% |
| Jun 30, 2021 | -201.72% |